ISIgor Boechat Silveira

Igor Boechat Silveira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Igor Boechat Silveira has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Meta‐Analysis: The Placebo Response in Modern Treatments for Cholestatic Pruritus: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

    by Igor Boechat Silveira, Leonardo Corrêa Süffert, Gustavo André Pedral Diniz Leite, Milena Ramos Tomé, Sarah Quick Lourenço de Lima, Gabriel André Pedral Diniz Leite, Bernardo de Faria Moraes, Pedro Robson Costa Passos, Guilherme Grossi Lopes Cançado

    Background/Aims: Cholestatic pruritus is a debilitating symptom with substantial placebo responses. We aimed to quantify this response and identify trial‐level moderators in randomized controlled trials of contemporary therapies. Methods: We performed a systematic review and meta‐analysis of placebo‐controlled trials evaluating ileal bile acid transporter inhibitors or PPAR agonists (searched through March 2026, with a supplementary search on 11 July 2026). Primary outcomes included the standardized mean change (SMC) of pruritus intensity, placebo response rate and mean difference (MD) in Numerical Rating Scale (NRS) and Worst–Itch NRS (WI‐NRS) scores. Secondary outcomes included PBC‐40 and 5‐D Itch scores. We used random‐effects models with Hartung–Knapp adjustment and meta‐regression. Results: Thirteen trials ( n = 548) were analysed. Across placebo groups, pruritus intensity decreased significantly from baseline during follow‐up periods of up to 52 weeks. The pooled SMC was −0.49 (95% CI, −0.72 to −0.27) overall, and −0.57 (95% CI, −0.81 to −0.33) for moderate‐to‐severe pruritus. Pooled response rates were 30.0% (overall) and 27.4% (moderate‐to‐severe). In moderate‐to‐severe patients, NRS showed a significant mean reduction of −1.62, whereas the WI‐NRS change (−0.65) was not statistically significant. Significant reductions occurred in the PBC‐40 itch domain (−2.02) and overall score (−9.13), while 5‐D Itch changes were non‐significant. None of the evaluated moderators were statistically significant. Conclusions: The magnitude of placebo‐associated improvement differed across outcome instruments and may affect estimates and interpretation of treatment effects in cholestatic‐pruritus trials. These findings may inform endpoint selection and assumptions used in future trial design. Trial Registration: PROSPERO registration number: CRD420261385974

  • Open Access

    Primary Sclerosing Cholangitis Recurrence After Liver Transplantation: A Systematic Review and Updated Meta‐Analysis

    by Isabelle Castro Vitor, Milena Ramos Tomé, Wellgner Fernandes Oliveira Amador, Igor Boechat Silveira, Marina de Assis Bezerra Cavalcanti Leite, Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Mariana Macambira Noronha, Yohanna Idsabella Rossi, Guilherme Grossi Lopes Cançado, et al.

    Background and Aims: Primary sclerosing cholangitis (PSC) is an immune‐mediated cholestatic liver disease. Liver transplantation (LT) remains the only definitive treatment for patients with advanced disease. However, recurrence of PSC (rPSC) after LT is still a significant clinical challenge. The aim of this study was to assess the prevalence and incidence of rPSC following transplantation and to identify factors associated with its occurrence. Methods: We conducted a systematic review and meta‐analysis of observational cohorts by searching PubMed, Embase and Cochrane for studies. Statistical analyses were conducted using R, applying a random‐effects model with 95% confidence intervals. Results: Twenty‐nine studies were included, comprising 4682 patients who underwent LT for PSC (63.7% male). Most data originated from Europe (51.7%) and North America (29.2%), with additional cohorts from Asia (13.7%), South America (2.8%) and Oceania (2.6%). The worldwide pooled prevalence of rPSC was 18.66% (95% CI 15.33–22.52; I 2 = 84%) between 1980 and 2024. As for the worldwide pooled incidence, rPSC occurred at 26.04 per 1000 person‐years (95% CI 19.30–32.78; I 2 = 76.1%). The continent with the highest rPSC prevalence was Oceania with 30.65% (95% CI 23.17–39.29; I 2 = 13.8%) and South America had the highest incidence with 39.97 per 1000 person‐years (95% CI 25.42–54.51). Younger recipient age (mean difference [MD] = 5.16 years, 95% CI 4.13–6.19; I 2 = 51.3%), male sex (risk ratio [RR] = 0.92, 95% CI 0.87–0.98; I 2 = 0%), post‐LT cyclosporine use (RR = 0.56, 95% CI 0.42–0.76; I 2 = 0%), acute rejection (RR = 0.64, 95% CI 0.49–0.83) and de novo IBD (RR = 0.63, 95% CI 0.40–0.99; I 2 = 0%) were associated with an increased risk of recurrence. Conclusions: Prevalence and incidence of rPSC post‐LT varied according to continents. Younger recipient age, male sex, de novo IBD, cyclosporine use post‐LT and acute rejection episodes were associated with a higher risk of recurrence. Trial Registration: PROSPERO ID: CRD420250645485


  • Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply

    by Bernardo de Faria Moraes, Igor Boechat Silveira, Gabriel André Pedral Diniz Leite, Maria Luisa Motta Fonseca, Leonardo Corrêa Suffert, Luisa Medeiros Visentini, Luis Pedro Possapp Beis, Guilherme Grossi Lopes Cançado

  • Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis—Authors' Reply

    by Bernardo de Faria Moraes, Igor Boechat Silveira, Gabriel André Pedral Diniz Leite, Maria Luisa Motta Fonseca, Leonardo Corrêa Suffert, Luisa Medeiros Visentini, Luis Pedro Possapp Beis, Guilherme Grossi Lopes Cançado

  • Recurrent primary biliary cholangitis after liver transplantation: A global meta-analysis of epidemiology and risk factors

    by Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Mariana Macambira Noronha, Yohanna Idsabella Rossi, Isabelle Castro Vitor, Milena Ramos Tomé, Wellgner Fernandes Oliveira Amador, Igor Boechat Silveira, Marina de Assis Bezerra Cavalcanti Leite, Rodrigo Vieira Motta, et al.


  • Open Access

    Ileal Bile Acid Transporter Inhibitors for Adult Patients with Autoimmune Cholestatic Liver Diseases: A Systematic Review and Meta-Analysis

    by Igor Boechat Silveira, Rodolfo Augusto Assis Rezende, Carlos Alberto Monteiro Leitão Neto, Yohanna Idsabella Rossi, Marina de Assis Bezerra Cavalcanti Leite, Guilherme Grossi Lopes Cançado

    Background: Autoimmune cholestatic liver diseases (AICLDs), including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are characterized by progressive biliary injury and cholestasis, leading to an impaired quantity/quality of life. Pruritus affects 20–70% of patients and is often refractory to current treatments. Ileal bile acid transporter (IBAT) inhibitors reduce bile acid reabsorption and may alleviate cholestatic pruritus. This systematic review and meta-analysis evaluates their efficacy and safety in adults with AICLD. Methods: Following PRISMA guidelines, we systematically searched PubMed, Embase, and Cochrane-CENTRAL for studies assessing IBAT inhibitors in adult AICLD patients with pruritus for ≥12 weeks. The primary outcome was the change in the 5-D Pruritus Scale. Secondary outcomes included sleep quality, serum bile acids, liver biochemistry, and safety. Heterogeneity was assessed using Cochrane Q and I2 statistics. Results: Three studies (n = 180) met inclusion criteria, including two RCTs and one single-arm study. Patients (78% female; 85% PBC; 77% linerixibat) showed a significant pruritus reduction (MD = −4.93, 95%CI [−6.26, −3.59], p < 0.0001), accompanied by improved sleep quality (MD = −8.12, 95%CI [−13.54, −2.70], p = 0.0033). Serum bile acids, FGF19, and autotaxin decreased significantly, with increased C4 levels. AST and GGT declined, while ALP, ALT, and bilirubin remained stable. Adverse events occurred in 89.7%, mainly diarrhea (22.7%), nausea (12.2%), and abdominal pain (18.2%); serious events were rare (2.2%). Conclusions: IBAT inhibitors significantly reduce pruritus and improve sleep in AICLD, with a favorable safety profile. These findings support their potential as a novel therapeutic option for cholestatic pruritus in adults with AICLD.


  • Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption and liver-related outcomes: A systematic review and meta-analysis

    by Bernardo de Faria Moraes, Gustavo André Pedral Diniz Leite, Igor Boechat Silveira, Nathália Veloso Lana, Guilherme Grossi Lopes Cançado